Skip to the reading [Peptide Studies](/) [Study leaves](/tirzepatide) [The sources](/references) [Our approach](/about) We read peptide research one study at a time, keeping what happened beside what remains unshown. - [Peptide Studies](/) - References # The papers stay within reach of the story. These are the sources we link to in Peptide Studies. Each note says what we used it for. A trial, a review and prescribing information do different jobs, even when they discuss the same compound. ## The human weight trial and the rat tendon experiment The opening page moves from people to rats. These sources help keep that change clear, with separate safety and human-evidence context. - ### [The semaglutide weight trial](https://pubmed.ncbi.nlm.nih.gov/33567185/) Wilding and colleagues, 2021. Adults without diabetes received semaglutide or placebo. This is where the opening weight comparison comes from. - ### [The semaglutide safety review](https://pubmed.ncbi.nlm.nih.gov/34305810/) Smits and Van Raalte, 2021. We use this review for digestive effects and gallbladder risk. It adds safety context to the account. - ### [BPC-157 and a cut rat Achilles tendon](https://pubmed.ncbi.nlm.nih.gov/14554208/) Staresinic and colleagues, 2003. This is the tendon-healing experiment. It also reports the separate work on tendon cells outside the rats. - ### [The later review of BPC-157 repair research](https://pubmed.ncbi.nlm.nih.gov/40789979/) McGuire and colleagues, 2025. We use this review to explain the very limited human evidence. It identifies the need for larger, rigorous trials. ## The tirzepatide and retatrutide leaves The weight trials provide comparisons within each study. The other sources explain targets, safety and approval; they aren't extra weight-loss trials. - ### [The tirzepatide obesity trial](https://pubmed.ncbi.nlm.nih.gov/35658024/) Jastreboff and colleagues, 2022. The source for weight changes over 72 weeks. It also reports the digestive side effects. - ### [Tirzepatide prescribing information](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b) The source for warnings about severe digestive problems and kidney injury linked to fluid loss. It also covers slow stomach emptying. - ### [The early retatrutide obesity trial](https://pubmed.ncbi.nlm.nih.gov/37366315/) Jastreboff and colleagues, 2023. This 48-week trial supplies the weight finding. It also reports digestive effects and increased heart rate. - ### [Retatrutide's three receptor targets](https://pmc.ncbi.nlm.nih.gov/articles/PMC11255275/) Research on how retatrutide interacts with three hormone receptors. We use it to explain the targets, rather than predict a personal benefit. - ### [A review of retatrutide's early research](https://pmc.ncbi.nlm.nih.gov/articles/PMC12190491/) Katsi and colleagues, 2025. This brings early findings together. We use it for context on the weight results and side effects. - ### [FDA information on unapproved GLP-1 drugs](https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss) The source for retatrutide's lack of FDA approval. An encouraging research result doesn't change that distinction. ## The tesamorelin and PT-141 leaves These papers measure different things: fat around the organs, desire and distress. The prescribing information keeps approved uses and safety warnings close by. - ### [The tesamorelin trial in adults with HIV](https://pubmed.ncbi.nlm.nih.gov/18057338/) Falutz and colleagues, 2007. The source for the visceral-fat result over 26 weeks. We use the paper's percentages in our account. - ### [Tesamorelin prescribing information](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75) The source for the approved use and weight-neutral description. It also supplies the blood-sugar, growth-signal and active-cancer cautions. - ### [The longer tesamorelin follow-up](https://pubmed.ncbi.nlm.nih.gov/18690162/) Falutz and colleagues, 2008. This supports the note about visceral fat returning after treatment stopped. It is separate from the first trial report. - ### [The two bremelanotide desire trials](https://pubmed.ncbi.nlm.nih.gov/31599840/) Kingsberg and colleagues, 2019. The source for changes in desire and related distress over 24 weeks. It also reports common side effects. - ### [Bremelanotide prescribing information](https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8c9607a2-5b57-4a59-b159-cf196deebdd9) The source for the approved population and temporary blood-pressure rise. It also explains the limits for people with certain cardiovascular conditions. A link supports the statement beside it. It doesn't settle every question about that compound. If a claim seems bigger than the account, returning to the original paper is a good way to see where the difference begins. [Opening accounts](/#study-accounts) [Retatrutide](/retatrutide) [Tesamorelin](/tesamorelin) [PT-141](/pt-141) [References](/references) [About](/about) [Contact](/contact) Peptide Studies is a place to read a paper carefully—a guide to the research, never a clinic, pharmacy or seller. © 2026 Peptide Studies